Kilograms decide how many 3 mg ivermectin tablets leave the tray

Why 3 mg ivermectin tablets are human-only

Human tablets only. The hub will not stamp a paste as a 3 mg ivermectin tablet.

The MDH tray stamps 3 mg ivermectin tablets as a human product. Stromectol and its generic are weight-based, usually 200 mcg per kg for the common gut-worm indication, which is a calculated tablet count, not a paste from a feed store.

Livestock formulations are a different concentration with different inactive ingredients. People who treat an online paste as a cheap 3 mg ivermectin tablet have ended up in emergency rooms. The hub will not blur those products.

MDH does not sell. A licensed human 3 mg quote is a scripted fill at a US counter. The tray wants a weight and a species before it names a pack of four or six.

Online paste is not a tray fill

Paste stays off this tray. Four or six human 3 mg tablets are quote sizes, not a DIY conversion.

Paste listings travel on the same search page as human tablets. That is a hold. Online paste is not a tray fill, not a generic swap, and not a cheaper 3 mg ivermectin tablet. The hub leaves those links off the card.

The human tablet is 3 mg. The paste is often many milligrams per mL meant for a horse. Arithmetic that just divides still misses the vehicle and the fact that the paste was never labeled for you.

If someone already took a paste, that is a poison-control conversation, not a coupon. MDH keeps the human row clean.

Human 3 mg quotes at four counters

Human 3 mg packs only. The hub is not a cart and will not quote a paste.

Four counters, this order: Target, Costco, Albertsons, Sam's Club. Packs are human 3 mg tablets, four or six, so the bands track a real Stromectol-class fill, not a livestock listing.

Human 3 mg bands for August 2026 sit at four counters. Script required. We do not sell. 3 mg ivermectin tablets on this hub stay human-only.

River blindness and strongyloides, not a COVID tablet

This antiparasitic has a narrow, well-defined job. Most of the trouble around it comes from using it for things it does not treat.

River-blindness campaigns made this tablet one of the most consequential antiparasitics ever made. Its discoverers shared a Nobel Prize because, at population scale, it has pushed river blindness and lymphatic filariasis toward elimination in regions where they once blinded and disabled millions. That track record is the reason to take it seriously as a drug and to be precise about what it does.

In everyday practice it is the first-line treatment for strongyloidiasis, a persistent gut worm that can smolder for decades and turn deadly if a patient is later immunosuppressed. It is also a dependable option for scabies, particularly the crusted form or outbreaks in institutions where topical treatment of everyone is impractical, and for head lice and certain other parasites.

It works against a defined list of parasites and nothing else. It is not an antibiotic, not an antiviral, and not a general anti-inflammatory. The wave of interest in it as a COVID-19 treatment ran far ahead of the evidence, and well-conducted trials have not shown a benefit. It is worth saying that plainly to patients who ask, because the confusion is common and the animal-formulation overdoses that followed were real harms.

The drug comes as a tablet for most human uses, dosed by weight. There are also topical formulations for skin conditions like rosacea and lice. The key point for any oral use is that the dose is calculated from the patient's weight rather than handed out as a standard number of pills.

For the right infection, ivermectin is close to ideal: a short course, often a single dose, that is cheap, well tolerated, and highly effective. The skill is not in giving it but in confirming the diagnosis and, in the wrong geography, screening for the one co-infection that makes it dangerous.

Glutamate chloride channels freeze the worm; human nerves mostly lack them

A glutamate chloride channel jams open in parasites have and our peripheral nerves do not, and the blood-brain barrier keeps it away from the channels we do share.

Glutamate-gated chloride channels are the bind site, which sit on the nerve and muscle cells of invertebrates like worms and mites. Locking these channels open floods the cell with chloride, hyperpolarizes it, and paralyzes the parasite. A paralyzed worm cannot feed, hold its position, or reproduce, and the host's immune system clears it.

The reason this is so safe for humans is elegant. People do not have those particular glutamate-gated chloride channels in their peripheral nerves and muscles. We do have related channels in the brain, but they are behind the blood-brain barrier, and a protein pump called P-glycoprotein actively kicks ivermectin back out of the brain before it can accumulate. The parasite has the vulnerable target exposed; we keep ours locked away.

That barrier is the whole safety story, and it explains the rare exceptions. Drugs or conditions that disable P-glycoprotein, or the immature barrier in very young children, can let more ivermectin into the brain and produce neurological effects. It is also why certain dog breeds with a genetic pump defect are famously sensitive to it, a useful mental hook for the mechanism.

A practical limitation flows from the mechanism. Ivermectin is superb at killing the larval and microfilarial stages of many parasites but often does not kill the adult worms. In river blindness the adult worms keep producing new microfilariae, so a single dose clears the load but the infection returns, which is why treatment is repeated periodically rather than given once.

Because it kills the parasite rather than dissolving it, some of ivermectin's most notable reactions are actually the immune response to large numbers of dying parasites, not toxicity from the drug itself. Keeping that distinction clear helps you interpret what happens after a dose in a heavily infected patient.

Oral absorption is good; the half-life stretches across a day

Oral uptake of this 3 mg tablet is reliable, and a fatty meal actually increases how much gets into the bloodstream. For most single-dose treatments the tablets are simply taken with water, but the food effect matters when higher tissue levels are wanted, as in some skin parasite regimens.

Half-life stretches long, on the order of eighteen hours for the parent drug and longer for its metabolites, so a single dose keeps working for days. That durability is why a one-time dose can clear an infection and why, for conditions like scabies, a repeat dose a week or two later mops up mites that hatched from eggs the first dose did not reach.

The liver handles metabolism, largely through the CYP3A4 enzyme system, and the drug and its metabolites are cleared mostly in the feces rather than the urine. Kidney function is therefore not the main concern with dosing, which is a helpful contrast with a drug like furosemide whose whole behavior pivots on the kidney.

Because CYP3A4 does the metabolizing, strong inhibitors or inducers of that enzyme can in theory shift ivermectin levels, though clinically significant interactions are uncommon at the single doses used for most infections. The interaction that gets more attention is with other drugs that affect the P-glycoprotein pump guarding the brain.

The long duration and tissue distribution are what make weight-based single dosing so effective. You are not relying on steady daily levels; you are delivering one pulse of drug high enough and long enough to paralyze the target, then letting the body clear both the drug and the parasite over the following days.

Two hundred mcg per kg is a count of 3 mg tablets, not a paste scoop

Two hundred micrograms per kilogram is the common target, calculated from weight and sometimes repeated to catch a second parasite generation.

Weight math is the dosing rule that ivermectin is weight-based. Most treatments work out to roughly 200 micrograms per kilogram, so a 70 kg adult gets about 14 mg. Because tablets come in fixed strengths, the actual number of tablets is calculated from the patient's weight, and skipping that math is the classic error.

For strongyloidiasis, the standard is 200 micrograms per kilogram, often as a single dose, though a second dose is sometimes given to be sure, and in disseminated disease treatment is more intensive and prolonged. This is the indication where getting the parasite fully cleared matters most, because a missed strongyloides infection can explode into a life-threatening hyperinfection if the patient is later given steroids or other immunosuppression.

For river blindness the dose is lower, around 150 micrograms per kilogram, and the defining feature is repetition. Since the drug spares the adult worms, treatment is repeated every several months to years to keep the microfilarial load down and prevent the eye and skin damage the parasite causes. It controls rather than cures.

For scabies, a weight-based dose repeated one to two weeks later is the norm, timed to catch mites that hatch from eggs after the first dose. Crusted scabies, which carries an enormous mite burden, may need several doses combined with topical treatment. Ordinary scabies is often treated topically first, with oral ivermectin reserved for failures, outbreaks, or patients who cannot apply a cream reliably.

Very young children and very small infants are generally not given oral ivermectin at standard doses because their blood-brain barrier is less mature, which is one of the few hard limits on an otherwise forgiving drug. When in doubt about weight thresholds or an unusual parasite, this is a drug where confirming the regimen is worth the extra minute.

The repeat-dose logic for scabies is worth spelling out, because it is the single most common place dosing goes wrong. A first dose kills the crawling mites but not reliably the eggs, which hatch over the following days. Giving a second weight-based dose about a week or two later catches that newly hatched generation before it can breed, and skipping it is why a patient who improved briefly returns still itching and still infested. Pairing the oral drug with a topical scabicide, and treating close contacts at the same time, closes the remaining gaps.

P-gp and CYP3A4 partners are few; Loa loa is the real hold

Partners on this card are few and mostly theoretical. The interaction that actually hurts people is with a heavy Loa loa co-infection.

The interaction card stays relatively clean, which is part of why it is used so widely in mass treatment programs where careful individual review is impossible. At the single doses used for most infections, the list of drugs that meaningfully change its behavior is short.

The interaction with the most theoretical weight involves P-glycoprotein, the pump that keeps ivermectin out of the brain. Drugs that strongly inhibit that pump could, in principle, raise brain exposure and neurological risk. In practice this is rarely a clinical problem at normal doses, but it is the mechanism behind the caution.

Because CYP3A4 metabolizes it, strong inhibitors of that enzyme could raise ivermectin levels and strong inducers could lower them. For a single-dose treatment this seldom matters, but it is worth a glance in a patient on multiple long-term medications, particularly if repeated or higher dosing is planned.

There is a caution about combining ivermectin with other drugs that increase central nervous system depression, again through the theme of central effects if the brain barrier is compromised. This is more relevant in overdose or in the vulnerable populations already mentioned than in a healthy adult taking a single correct dose.

The most dangerous drug interaction is arguably not a drug at all but a co-infection. In regions where the Loa loa worm circulates, giving ivermectin to someone with a very high parasite load can trigger a severe brain reaction, so the practical rule in those settings is to screen the blood before treating rather than to worry about the pharmacy shelf.

Itch and dizziness often come from dying parasites, not the tablet

At a calculated 3 mg count the tablet is gentle. The dramatic reactions are usually the immune response to dying parasites or the specific Loa loa danger.

At labeled mcg/kg in an otherwise healthy person, ivermectin is remarkably well tolerated. Most people take it with no more than mild, transient effects, which is exactly why it can be given to millions of people in community programs with minimal supervision.

The reactions that do occur in a heavily infected patient are frequently not toxicity from the drug but the immune system's response to a mass of dying parasites. In river blindness this is called a Mazzotti reaction: itching, rash, swollen tender lymph nodes, fever, and joint aches that appear in the day or two after treatment. It reflects a big parasite load being killed, and it settles as the dead microfilariae clear.

Direct side effects of the drug itself tend to be minor: some dizziness, nausea, a bit of drowsiness, or mild abdominal discomfort. These are the kinds of complaints that come with a single-dose medication and rarely require anything beyond reassurance.

The serious neurological reactions are the exception and are tied to the specific scenarios where the drug reaches the brain: the Loa loa encephalopathy in heavily co-infected patients, and the vulnerability in the very young or in those with a compromised blood-brain barrier. Outside these settings, central toxicity from a correct dose is not expected.

The overdose harms that made headlines came almost entirely from people taking concentrated veterinary formulations meant for large animals, at doses far beyond anything used in humans. That is a poisoning story, not a reflection of the human drug taken correctly, and it is worth distinguishing clearly when a patient raises it.

Screen Loa loa; hold in pregnancy; infants below the weight cut stay off

This tablet is forgiving except at the edges: the very young, pregnancy, and, above all, the immunosuppressed patient with hidden strongyloides.

Very small children and infants below common weight thresholds are generally not given oral ivermectin, because the blood-brain barrier that protects the rest of us is less developed early in life. This is one of the clearest limits on the drug and the reason weight, not just age, guides eligibility.

In pregnancy, ivermectin is usually avoided for routine treatment and reserved for situations where the benefit clearly outweighs uncertainty, because safety data are limited rather than alarming. Many mass-treatment programs simply exclude pregnant women as a precaution and treat them later.

The immunosuppressed patient is where strongyloidiasis becomes a matter of life and death. A quiet, long-standing strongyloides infection can erupt into an overwhelming hyperinfection when someone is given steroids like prednisolone or other immunosuppressants. Screening and treating strongyloides before planned immunosuppression is a genuine, evidence-based safety step, not a formality.

In regions where Loa loa is endemic, the special population is defined by geography and parasite load rather than by age or organ function. Anyone from those areas with a very high Loa loa count needs a modified approach, because a standard ivermectin dose can precipitate a brain emergency. This is the single most important population-level caution with the drug.

Liver disease deserves a thought, since the liver clears the drug, but the short courses used for most infections rarely cause problems. As with the vulnerable groups above, the theme is that ivermectin is forgiving for the ordinary patient and demands specific caution only in a few well-defined situations.

Name the worm first, then prove the stool or skin is clear

Species and Loa loa checks happen before the dose, in diagnosis and Loa loa screening, and afterward in confirming strongyloides is truly gone.

Watching this 3 mg course is less about drug toxicity and more about confirming you are treating the right thing and that it worked. The upfront work is diagnosis: identifying the parasite, and in the right geography, screening for Loa loa before giving a dose. That screening is the highest-value monitoring step in endemic areas.

For strongyloidiasis, follow-up matters because the goal is eradication, not just improvement. Because the parasite can persist and later cause hyperinfection, clinicians often recheck stool studies or serology after treatment to be confident the infection is gone, particularly before any planned immunosuppression.

For scabies, the monitoring is clinical and practical. Itching can persist for a couple of weeks even after the mites are dead, so you counsel patients not to interpret ongoing itch as failure, while watching for genuine signs of persistent infestation that would justify a repeat course.

In river blindness programs, monitoring is done at the population level, tracking microfilarial loads and disease rates over years, because the drug controls rather than cures and treatment must be sustained. For an individual, the point is to keep returning for repeat doses rather than assuming one treatment settled it.

In the rare patient who develops neurological symptoms after a dose, monitoring becomes urgent and clinical: this is the Loa loa or barrier-compromise scenario, and it is managed as a medical emergency rather than something to observe at home. For the ordinary single-dose patient, no routine blood monitoring is required at all.

Human 3 mg only; livestock paste and COVID rumors stay off the card

Kill the COVID rumor, explain weight-based dosing, and warn heavily infected patients that a reaction to dying parasites is normal.

Name the parasite first, then say what the drug is for. A patient who has heard about ivermectin online often has the wrong idea about its uses, and a plain statement that it treats specific parasites, and that good trials do not support it for viral illnesses like COVID-19, prevents both false hope and dangerous self-medication with animal products.

Explain the dosing logic. Because the dose depends on weight, patients should not share tablets, guess, or take leftover pills from someone else. If a repeat dose is part of the plan, as it often is for scabies, tell them when and why, so they do not assume the treatment failed when a second dose was always intended.

Warn heavily infected patients about the reaction to dying parasites. Someone treated for river blindness who develops itching, fever, and swollen glands over the next day or two should know this is expected and self-limited, not an allergy to the tablet. Framing it in advance turns a frightening experience into an anticipated one.

For scabies specifically, counsel that itching outlasts the mites. Skin can stay irritated and itchy for a couple of weeks after successful treatment, and patients who expect instant relief may over-treat or worry unnecessarily. Setting that expectation is part of a successful course.

Finally, take the geography question seriously. Ask patients from Loa loa regions about their travel and origin, and route anyone with a relevant exposure and a heavy parasite burden to appropriate screening. When a patient is unsure whether ivermectin is right for their situation, the safe advice is to discuss it with a clinician rather than self-treat.

Reinfection, a missed species, or a paste someone treated as a tablet

A missed worm, reinfection, or a missed repeat dose, not the parasite outsmarting the drug.

A miss often means the species was wrong. Ivermectin treats a specific set of parasites, so a patient whose symptoms persist may have a different organism, a bacterial or fungal problem, or a non-infectious condition entirely. Before repeating or escalating, the first move is to confirm the parasite is really there.

Reinfection is the next common reason, especially with scabies in a household or institution. If everyone in close contact is not treated and the environment not addressed, the mites simply cycle back. A single treated patient in an untreated home will keep getting scabies, and no amount of ivermectin fixes a shared problem treated one person at a time.

For scabies, remember the egg gap. A single dose does not reliably kill eggs, so mites hatching afterward can look like failure when the real issue is that a planned second dose was never given. The fix is the scheduled repeat dose, not a conclusion that the drug does not work.

In river blindness and similar filarial diseases, the return of microfilariae is not failure at all; it is the expected consequence of a drug that spares adult worms. Treatment is meant to be repeated, and a patient or program that stops after one round will see the disease resurface. This is control, and it requires persistence.

Genuine drug resistance in human parasites is far less of a concern than it is in veterinary medicine, where heavy repeated use has selected resistant worms in livestock. In people, when ivermectin truly does not work, the answer is almost always a wrong diagnosis, reinfection, or an incomplete course rather than a resistant parasite.

Kilograms set the 3 mg count; species and Loa loa sit before the pack

This 3 mg tablet is an excellent, well-tolerated antiparasitic with a defined job: strongyloidiasis, river blindness, scabies, and a handful of other parasites. It paralyzes the parasite through channels our peripheral nerves lack, and the blood-brain barrier keeps us safe, which is the whole reason it is so gentle.

Count 3 mg tablets by kilograms, every time, and remember that a single dose is often enough but sometimes needs a repeat to catch the next generation. Screen for Loa loa before treating anyone from an endemic region, and treat hidden strongyloides before immunosuppression, because that is where the drug quietly saves lives.

It is not an antiviral. The evidence does not support it for COVID-19, and the harms that made news came from people taking concentrated veterinary products. Say that clearly and you spare patients both false hope and real poisoning.

Used for the right parasite, in the right dose, with an eye on the two or three genuine danger scenarios, ivermectin is close to an ideal drug: cheap, effective, and safe. The judgment is all in the diagnosis and the geography, not in the swallowing of the tablet.